CG347B

Overview

CG347B is a selective HDAC6 inhibitor, also involves in synthesis of other metalloenzyme inhibitors. HDAC6 inhibitors can be used for oncology, immunology, and neurology research.

Application

Products | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Neurological Disease | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > HDAC

Product Information

• Catalog No.: HY-135890
• CAS No.: 1598426-03-9
• Molecular Formula: C16H17N3O2
• Molecular Weight: 283.33
• Purity: 98.07%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 6.25 mg/mL (22.06 mM); Clear solution
• Availability: In-stock

Source

Original product source